Evidence map›Paper›PMID 26845040›Full record

ArticlePloS one2016

Adiponectin Upregulates MiR-133a in Cardiac Hypertrophy through AMPK Activation and Reduced ERK1/2 Phosphorylation.

Ying Li, Xiaojun Cai, Yuqing Guan, Lei Wang, Shuya Wang, Yueyan Li, Ying Fu, Xiaoyuan Gao, Guohai Su

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Dysregulated miRNAs Targeting Adiponectin Signaling in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Cardiovascular disease and depression: a narrative review.Frontiers in cardiovascular medicine · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ying LiDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Xiaojun CaiDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Yuqing GuanDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Lei WangDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Shuya WangSchool of Medicine, Shandong University, Jinan, China.
Yueyan LiDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Ying FuSchool of Medicine, Shandong University, Jinan, China.
Xiaoyuan GaoDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Guohai SuDepartment of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Shandong University · CNJinan Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adiponectin and miR-133a are key regulators in cardiac hypertrophy. However, whether APN has a potential effect on miR-133a remains unclear. In this study, we aimed to investigate whether APN could regulate miR-133a expression in Angiotensin II (Ang II) induced cardiac hypertrophy in vivo and in vitro. Lentiviral-mediated adiponectin treatment attenuated cardiac hypertrophy induced by Ang II infusion in male wistar rats as determined by reduced cell surface area and mRNA levels of atrial natriuretic peptide (ANF) and brain natriuretic peptide (BNP), also the reduced left ventricular end-diastolic posterior wall thickness (LVPWd) and end-diastolic interventricular septal thickness (IVSd). Meanwhile, APN elevated miR-133a level which was downregulated by Ang II. To further investigate the underlying molecular mechanisms, we treated neonatal rat ventricular myocytes (NRVMs) with recombinant rat APN before Ang II stimulation. Pretreating cells with recombinant APN promoted AMP-activated protein kinase (AMPK) phosphorylation and inhibited ERK activation. By using the inhibitor of AMPK or a lentiviral vector expressing AMPK short hairpin RNA (shRNA) cancelled the positive effect of APN on miR-133a. The ERK inhibitor PD98059 reversed the downregulation of miR-133a induced by Ang II. These results indicated that the AMPK activation and ERK inhibition were responsible for the positive effect of APN on miR-133a. Furthermore, adiponectin receptor 1 (AdipoR1) mRNA expression was inhibited by Ang II stimulation. The positive effects of APN on AMPK activation and miR-133a, and the inhibitory effect on ERK phosphorylation were inhibited in NRVMs transfected with lentiviral AdipoR1shRNA. In addition, APN depressed the elevated expression of connective tissue growth factor (CTGF), a direct target of miR-133a, through the AMPK pathway. Taken together, our data indicated that APN reversed miR-133a levels through AMPK activation, reduced ERK1/2 phosphorylation in cardiomyocytes stimulated with Ang II, revealing a previously undemonstrated and important link between APN and miR-133a.

Indexed as

Gene Expression RegulationAdiponectinAMP-Activated Protein KinasesAngiotensin IIAnimalsCardiomegalyConnective Tissue Growth FactorDisease Models, AnimalEchocardiographyGene ExpressionGenetic VectorsLentivirusMaleMicroRNAsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3AdiponectinAMP-Activated Protein KinasesAngiotensin IIConnective Tissue Growth FactorMicroRNAsMIRN133 microRNA, ratMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Receptors, Adiponectin

Identifiers

PMID26845040
PMCPMC4741527
OpenAlexW2260873510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.